Preoperative Therapy Using Trastuzumab and Weekly Paclitaxel in a Stage III B Inoperable Locally Advanced HER2-Positive Breast Cancer with Complete Pathologic Response

Author： Rai Yoshiaki   Sagara Yoshiatsu   Ooi Yasuyo   Yasuaki   Sagara Yoshiaki   Baba Shinichi   Tamada Syugo   Matsuyama Yoshito   Ando Mitsutake  

Publisher： Sunmedia

ISSN： 0385-0684

Source： Japanese Journal of Cancer and Chemotherapy, Vol.36, Iss.3, 2009-03, pp. : 471-473

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

By Gasparini Giampietro   Gion Massimo   Mariani Luigi   Papaldo Paola   Crivellari Diana   Filippelli Gianfranco   Morabito Alessandro   Silingardi Vittorio   Torino Francesco   Spada Antonella   Zancan Matelda   Sio Livia   Caputo Antonio   Cognetti Francesco   Lambiase Antonio   Amadori Dino  

Breast Cancer Research and Treatment, Vol. 101, Iss. 3, 2007-03 ,pp. : 355-365

Springer Publishing Company

Access to resources Recommend Favorite

Preoperative concurrent paclitaxel-radiation in locally advanced breast cancer: pathologic response correlates with five-year overall survival

By Adams Sylvia   Chakravarthy A.   Donach Martin   Spicer Darcy   Lymberis Stella   Singh Baljit   Bauer Joshua   Hochman Tsivia   Goldberg Judith   Muggia Franco   Schneider Robert   Pietenpol Jennifer   Formenti Silvia  

Breast Cancer Research and Treatment, Vol. 124, Iss. 3, 2010-12 ,pp. : 723-732

Springer Publishing Company

Access to resources Recommend Favorite

Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel

By Torrisi Rosalba  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 4, 2008-09 ,pp. : 667-672

Springer Publishing Company

Access to resources Recommend Favorite

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy

By Hurvitz Sara   Dalenc Florence   Campone Mario   O’Regan Ruth   Tjan-Heijnen Vivianne   Gligorov Joseph   Llombart Antonio   Jhangiani Haresh   Mirshahidi Hamid   Tan-Chiu Elizabeth   Miao Sara   El-Hashimy Mona   Lincy Jeremie   Taran Tetiana   Soria Jean-Charles   Sahmoud Tarek   André Fabrice  

Breast Cancer Research and Treatment, Vol. 141, Iss. 3, 2013-10 ,pp. : 437-446

Springer Publishing Company

Access to resources Recommend Favorite

SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer

By Livingston Robert   Barlow William   Kash Joseph   Albain Kathy   Gralow Julie   Lew Danika   Flaherty Lawrence   Royce Melanie   Hortobagyi Gabriel  

Breast Cancer Research and Treatment, Vol. 130, Iss. 1, 2011-11 ,pp. : 123-131

Springer Publishing Company

Access to resources Recommend Favorite